ADPT Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
71.6M
+1.0%
70.9M
-1.1%
71.7M
-23.7%
94.0M
+59.6%
58.9M
Cost of Revenue
20.2M
+7.8%
18.7M
+2.7%
18.2M
+0.4%
18.2M
+0.9%
18.0M
Gross Profit
51.4M
-1.5%
52.2M
-2.4%
53.5M
-29.5%
75.8M
+85.5%
40.9M
Operating Expenses
67.2M
-5.9%
71.4M
+7.8%
66.2M
+1.1%
65.5M
-0.6%
65.9M
R&D
19.2M
-18.9%
23.6M
+8.5%
21.8M
-8.1%
23.7M
-1.9%
24.1M
SG&A
47.6M
+0.5%
47.3M
+7.5%
44.0M
+6.3%
41.4M
+0.2%
41.4M
Operating Income
-15770000
+17.9%
-19206000
-50.4%
-12773000
-224.1%
10.3M
+141.1%
-25036000
EBITDA
-12075000
+21.4%
-15369000
-79.2%
-8578000
-158.4%
14.7M
+171.6%
-20534000
Net Income
-39941000
-99.6%
-20015000
-47.4%
-13579000
-242.3%
9.5M
+137.3%
-25593000
EPS (Basic)
$-0.25
-92.3%
$-0.13
-44.4%
$-0.09
-250.0%
$0.06
+135.3%
$-0.17
EPS (Diluted)
$-0.25
-92.3%
$-0.13
-30.0%
$-0.10
-266.7%
$0.06
+135.3%
$-0.17
Shares (Diluted)
159.9M
+2.8%
155.5M
+9.2%
142.4M
-12.7%
163.2M
+7.3%
152.1M
Adaptive Biotechnologies (ADPT) โ€” Financials